![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Onyx Pharmaceuticals, Inc. (MM) | NASDAQ:ONXX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 124.70 | 0 | 01:00:00 |
o
|
Rule
13d-1(b)
|
|
x
|
Rule
13d-1(c)
|
|
o
|
Rule
13d-1(d)
|
CUSIP No.
683399109
|
|||||||
1.
|
Names of Reporting Persons
I.R.S. Identification Nos. of
above persons (entities only)
D.
E. Shaw Valence Portfolios, L.L.C.
13-4046559
|
||||||
2.
|
Check the Appropriate Box if a
Member of a Group (See Instructions)
|
||||||
(a)
|
o
|
||||||
(b)
|
o
|
||||||
3.
|
SEC Use Only
|
||||||
4.
|
Citizenship or Place of
Organization
Delaware
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5.
|
Sole Voting Power
-0-
|
||||
6.
|
Shared Voting Power
3,263,941
|
|||||
7.
|
Sole Dispositive Power
-0-
|
|||||
8.
|
Shared Dispositive Power
3,263,941
|
|||||
9.
|
Aggregate Amount Beneficially
Owned by Each Reporting Person
3,263,941
|
|||||
10.
|
Check if the Aggregate Amount
in Row (9) Excludes Certain Shares (See Instructions)
o
|
|||||
11.
|
Percent of Class Represented by
Amount in Row (9)
5.8%
|
|||||
12.
|
Type of Reporting Person (See
Instructions)
OO
|
CUSIP No.
683399109
|
||||||
1.
|
Names of Reporting Persons
I.R.S. Identification Nos. of
above persons (entities only)
D.
E. Shaw & Co., L.P.
13-3695715
|
|||||
2.
|
Check the Appropriate Box if a
Member of a Group (See Instructions)
|
|||||
(a)
|
o
|
|||||
(b)
|
o
|
|||||
3.
|
SEC Use Only
|
|||||
4.
|
Citizenship or Place of
Organization
Delaware
|
|||||
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5.
|
Sole Voting Power
-0-
|
||||
6.
|
Shared Voting Power
3,269,241
|
|||||
7.
|
Sole Dispositive Power
-0-
|
|||||
8.
|
Shared Dispositive Power
3,275,741
|
|||||
9.
|
Aggregate Amount Beneficially
Owned by Each Reporting Person
3,275,741
|
|||||
10.
|
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions)
o
|
|||||
11.
|
Percent of Class Represented by
Amount in Row (9)
5.8%
|
|||||
12.
|
Type of Reporting Person (See
Instructions)
IA,
PN
|
CUSIP No.
683399109
|
||||||
1.
|
Names of Reporting Persons
I.R.S. Identification Nos. of
above persons (entities only)
David
E. Shaw
|
|||||
2.
|
Check the Appropriate Box if a
Member of a Group (See Instructions)
|
|||||
(a)
|
o
|
|
||||
(b)
|
o
|
|||||
3.
|
SEC Use Only
|
|||||
4.
|
Citizenship or Place of
Organization
United
States
|
|||||
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5.
|
Sole Voting Power
-0-
|
||||
6.
|
Shared Voting Power
3,269,241
|
|||||
7.
|
Sole Dispositive Power
-0-
|
|||||
8.
|
Shared Dispositive Power
3,275,741
|
9.
|
Aggregate Amount Beneficially
Owned by Each Reporting Person
3,275,741
|
|||||
10.
|
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions)
o
|
|||||
11.
|
Percent of Class Represented by
Amount in Row (9)
5.8%
|
|||||
12.
|
Type of Reporting Person (See
Instructions)
IN
|
Item 1.
|
||
(a)
|
Name of Issuer:
|
|
Onyx
Pharmaceuticals,
Inc.
|
||
(b)
|
Address of Issuer's Principal
Executive Offices:
|
|
2100
Powell Street
Emeryville,
California
94608
|
||
Item 2.
|
||
(a)
|
Name of Person Filing:
|
|
D.
E. Shaw Valence Portfolios, L.L.C.
D.
E. Shaw & Co., L.P.
David
E. Shaw
|
||
(b)
|
Address of Principal Business
Office or, if none, Residence:
|
|
The
business address for each reporting person is:
120
W. 45
th
Street, Tower 45, 39
th
Floor
New
York, NY 10036
|
||
(c)
|
Citizenship:
|
|
D.
E. Shaw Valence Portfolios, L.L.C. is a limited liability company
organized under the laws of the state of Delaware.
D.
E. Shaw & Co., L.P. is a limited partnership organized under the laws
of the state of Delaware.
David
E. Shaw is a citizen of the United States of
America.
|
||
(d)
|
Title of Class of Securities:
|
|
Common
Stock, $0.001 par
value
|
||
(e)
|
CUSIP Number:
|
|
683399109
|
Item 3.
|
If this statement is filed
pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person
filing is a:
|
|||
Not
Applicable
|
Item 4.
|
Ownership
|
|
As
of December 31, 2008:
(a)
Amount beneficially owned:
|
D.
E. Shaw Valence Portfolios, L.L.C.:
|
3,263,941
shares
This
is composed of (i) 3,161,641 shares in the name of D. E. Shaw Valence
Portfolios, L.L.C. and (ii) 102,300 shares that D. E. Shaw Valence
Portfolios, L.L.C. has the right to acquire through the exercise of listed
call
options.
|
D.
E. Shaw & Co., L.P.:
|
3,275,741
shares
This
is composed of (i) 3,161,641 shares in the name of D. E. Shaw Valence
Portfolios, L.L.C., (ii) 102,300 shares that D. E. Shaw Valence
Portfolios, L.L.C. has the right to acquire through the exercise of listed
call options, and (iii) 11,800 shares under the management of
D. E. Shaw Investment Management,
L.L.C.
|
David
E. Shaw:
|
3,275,741
shares
This
is composed of (i) 3,161,641 shares in the name of D. E. Shaw Valence
Portfolios, L.L.C., (ii) 102,300 shares that D. E. Shaw Valence
Portfolios, L.L.C. has the right to acquire through the exercise of listed
call options, and (iii) 11,800 shares under the management of
D. E. Shaw Investment Management,
L.L.C.
|
D.
E. Shaw Valence Portfolios, L.L.C.:
|
5.8%
|
|
D.
E. Shaw & Co., L.P.:
|
5.8%
|
|
David
E. Shaw:
|
5.8%
|
D.
E. Shaw Valence Portfolios, L.L.C.:
|
-0-
shares
|
|
D.
E. Shaw & Co., L.P.:
|
-0-
shares
|
|
David
E. Shaw:
|
-0-
shares
|
D.
E. Shaw Valence Portfolios, L.L.C.:
|
3,263,941
shares
|
|
D.
E. Shaw & Co., L.P.:
|
3,269,241 shares
|
|
David
E. Shaw:
|
3,269,241 shares
|
D.
E. Shaw Valence Portfolios, L.L.C.:
|
-0-
shares
|
|
D.
E. Shaw & Co., L.P.:
|
-0-
shares
|
|
David
E. Shaw:
|
-0-
shares
|
D.
E. Shaw Valence Portfolios, L.L.C.:
|
3,263,941
shares
|
|
D.
E. Shaw & Co., L.P.:
|
3,275,741 shares
|
|
David
E. Shaw:
|
3,275,741
shares
|
Item 5.
|
Ownership of Five Percent or
Less of a Class
|
|
Not
Applicable
|
||
Item 6.
|
Ownership of More than Five
Percent on Behalf of Another Person
|
|
Not
Applicable
|
||
Item 7.
|
Identification and
Classification of the Subsidiary Which Acquired the Security Being
Reported on By the Parent Holding Company or Control Person
|
|
Not
Applicable
|
||
Item 8.
|
Identification and
Classification of Members of the Group
|
|
Not
Applicable
|
||
Item 9.
|
Notice of Dissolution of Group
|
|
Not
Applicable
|
||
Item 10.
|
Certification
|
|
By
signing below, each of D. E. Shaw Valence Portfolios, L.L.C.,
D. E. Shaw & Co., L.P., and David E. Shaw certify
that, to the best of such reporting person’s knowledge and belief, the
securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having such
purposes or effect.
|
|
D.
E. Shaw Valence Portfolios, L.L.C.
|
||
|
By:
|
D.
E. Shaw & Co., L.P., as
managing
member
|
|
|
|
|
|
By: | /s/ Rochelle Elias | ||
|
|
|
Rochelle
Elias
Chief
Compliance Officer
|
D. E. Shaw & Co., L.P. | ||
|
|
|
By: | /s/ Rochelle Elias | |
Rochelle
Elias
Chief
Compliance Officer
|
David E. Shaw | ||
|
|
|
By: | /s/ Rochelle Elias | |
Rochelle
Elias
Attorney-in-Fact
for David E.
Shaw
|
1 Year Onyx Pharmaceuticals, Inc. (MM) Chart |
1 Month Onyx Pharmaceuticals, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions